Zachary Jennifer 4

What Happened

• Zachary Jennifer, a director of REGENXBIO, received equity awards on May 29, 2026: 9,807 shares in the form of time‑based restricted stock units (RSUs) and an award covering 46,600 option/derivative shares. Both grants show an acquisition price of $0.00 (no cash paid at grant).
• These are grants (Form 4 code A) — not open‑market purchases or sales — so they are compensation awards rather than immediate market trades.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026.
• Grant amounts and price: 9,807 RSU shares @ $0.00; 46,600 derivative/option shares @ $0.00.
• Vesting: RSU (F1) — 100% of the 9,807 shares vest May 29, 2027 subject to continuous service. Option (F2) — vests May 29, 2027 subject to continuous service.
• Shares owned after the transaction: not reported in the supplied filing details.
• Filing notes: these entries are reported as awards/derivative grants; no 10b5‑1 plan, sale, or tax‑withholding information is disclosed in the provided data.

Context

• RSUs represent a promise to deliver shares upon vesting; the 9,807 shares will convert to actual common stock only if the director remains in service through the vest date. The 46,600 figure reflects an option/derivative award that must vest and then be exercised before becoming tradable shares.
• Such grants are common components of executive/director compensation and do not reflect an immediate purchase or sale of stock in the open market.